G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
Sara AvalosRosa E MejiaEngels BanegasCesar SalinasLester GutierrezMarcela FajardoSuzeth GaloAlejandra PintoAngel MejiaGustavo Adolfo Fontecha SandovalPublished in: Malaria journal (2018)
The findings support that the intake of PQ during 14 days of treatment against vivax malaria is safe in patients with a class III variant of G6PDd. In view of the new national regulations in the shortened treatment of vivax malaria for 7 days, it is advisable to be alert of potential cases of severe haemolysis that could occur among G6PD deficient hemizygous males with a class II mutation such as the Santamaria variant, previously reported in the country.